RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Amyloidosis: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Characterization of Amyloidosis in Clinical Practice Using an Extended Panel of Immunohistochemistry
Vikarn Vishwajeet et al., Indian Journal of Hematology and Blood Transfusion (16 October 2026)
https://doi.org/10.1007/s12288-026-02603-4
- 2.
Molecular Identification of Transthyretin Amyloid in Fixed Skin Biopsies: A Simplified Sample Preparation Method
Rivka Goldis et al., Journal of Visualized Experiments (16 October 2026)
https://doi.org/10.3791/73230
- 3.
Disease progression in transthyretin cardiac amyloidosis treated with disease-modifying therapies: a multicenter real-world experience.
López-Calles Alba et al., Medicina clinica (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42887471/
- 4.
Cerebral Amyloid Angiopathy Caused by Immunoglobulin Light Chain Amyloidosis
Mohamad Ali Kesserwan et al., Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (15 October 2026)
https://doi.org/10.1017/cjn.2026.10702
- 5.
Tafamidis with versus without subsequent vutrisiran initiation in transthyretin amyloid cardiomyopathy: a two-database propensity-matched landmark study
Ma'in Abumuhfouz et al., BMC Cardiovascular Disorders (15 October 2026)
https://doi.org/10.1186/s12872-026-06788-4
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
NCT07224672 · Recruiting · Phase 2 · GlaxoSmithKline
Ages 18 and over
https://clinicaltrials.gov/study/NCT07224672
- 2.
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203 · Recruiting · Phase 3 · Alnylam Pharmaceuticals
Ages 18 to 85
https://clinicaltrials.gov/study/NCT07223203
- 3.
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811 · Recruiting · Phase 3 · Novo Nordisk A/S
Ages 18 and over
https://clinicaltrials.gov/study/NCT07207811
- 4.
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903 · Recruiting · Phase 3 · Alnylam Pharmaceuticals
Ages 18 to 85
https://clinicaltrials.gov/study/NCT07052903
- 5.
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895 · Recruiting · Phase 3 · Eidos Therapeutics, a BridgeBio company
Ages 18 to 75
https://clinicaltrials.gov/study/NCT06563895
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Amyloidosis
Amyloidosis is a group of conditions where abnormal proteins called amyloid fibres build up in organs, causing progressive organ damage. ATTR amyloidosis (transthyretin) and AL amyloidosis are the most common types. New RNA-based therapies and small molecule stabilisers have significantly improved outcomes.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Amyloidosis?
Amyloidosis is a group of conditions where abnormal proteins called amyloid fibres build up in organs, causing progressive organ damage. ATTR amyloidosis (transthyretin) and AL amyloidosis are the most common types. New RNA-based therapies and small molecule stabilisers have significantly improved outcomes.
How many clinical trials are available for Amyloidosis?
RareWays currently indexes 363 clinical trials for Amyloidosis, of which 70 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Amyloidosis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Amyloidosis.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.